NASDAQ$CSTL
Castle Biosciences Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Announced second quarter 2020 results, reflecting COVID-19 impacts but showing improvement in DecisionDx-Melanoma orders since April.
Castle Biosciences reported Q2 2020 revenues of $12.7 million, an 18% increase compared to Q2 2019. The company delivered 3,008 DecisionDx-Melanoma test reports, a 19% decrease year-over-year, and maintained a strong gross margin of 83%. Operating cash flow was positive at $13.5 million.
- Revenue increased by 18% to $12.7 million compared to Q2 2019.
- DecisionDx-Melanoma test report volume decreased by 19% compared to Q2 2019, but saw sequential gains throughout the quarter.
- Gross margin remained strong at 83%.
- Operating cash flow was positive, reaching $13.5 million.
Headline financials
Revenue & EPS history
Castle Biosciences · Revenue · Quarterly
$12.7M
Forward guidance
Castle Biosciences is moving forward with its planned commercial team expansion in the second half of 2020 and plans for DecisionDx-SCC to be commercially available at the beginning of September. They also expect a test for suspicious pigmented lesions to become commercially available in the second half of 2020.
Tailwinds
- Continued progress of pipeline tests allows expansion of services for patients with early-stage skin cancers.
- Planned commercial team expansion in the second half of 2020 to position for near- and long-term growth.
- DecisionDx-SCC is expected to be commercially available at the beginning of September.
- Clinical validation work completed for a pipeline test for use in suspicious pigmented lesions, expected to launch in the second half of 2020.
- Three skin cancer products (DecisionDx-Melanoma, DecisionDx-SCC, and the test for suspicious pigmented lesions) will have a total addressable U.S. market of approximately $2.0 billion.
Headwinds
- COVID-19 pandemic's impact on the Company’s future test report volumes, operating results, cash flows, results of operations and/or financial condition will be primarily driven by such variables as the pandemic's severity, duration and the impact of state and local government restrictions on the U.S. healthcare system, which the Company is unable to predict or control.
- Trends in test report volumes, order data and new ordering clinician data is not necessarily indicative of the Company’s results of operations that can be expected for future interim periods or for the year ending December 31, 2020.
- The number of new ordering clinicians (first time ordering a test) for DecisionDx-Melanoma decreased by 43% in the second quarter, compared to the same period in 2019
- Delivered 3,008 DecisionDx-Melanoma test reports in the second quarter of 2020, which represents a 19% decrease compared to the 3,691 reports delivered in the second quarter of 2019. The Company believes this decrease is the result of fewer patient visits to physicians during the quarter due to the COVID-19 pandemic.
- Delivered 306 DecisionDx-UM test reports in the second quarter of 2020, compared to 376 reports in the second quarter of 2019. The Company believes this decrease is the result of fewer patient visits to physicians during the quarter due to the COVID-19 pandemic.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+0.1%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+0.7%
Avg return
30 days after
41%
13 / 32 earnings
Positive
+21.8%
Q3 2025
Best reaction
-28.0%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -22.6% | -14.4% | |
| Q4 2025 | -7.3% | -11.6% | -26.2% | |
| Q3 2025 | +21.8% | +27.1% | +52.4% | |
| Q1 2025 | -11.7% | -10.5% | -9.2% | |
| Q4 2024 | -14.2% | -15.7% | -21.1% | |
| Q3 2024 | -6.0% | +0.4% | -3.8% | |
| Q2 2024 | +11.8% | +20.4% | +29.8% | |
| Q1 2024 | +10.5% | +8.1% | +5.6% | |
| Q4 2023 | -28.0% | -15.4% | -11.7% | |
| Q3 2023 | +14.5% | +14.6% | +27.2% | |
| Q2 2023 | +12.3% | +7.0% | +17.6% | |
| Q1 2023 | -0.2% | +2.6% | +3.0% | |
| Q4 2022 | -7.7% | -0.3% | -10.2% | |
| Q3 2022 | -6.0% | -23.7% | -0.4% | |
| Q2 2022 | +0.3% | +11.1% | -12.6% | |
| Q1 2022 | -4.1% | -6.8% | +3.1% | |
| Q4 2021 | +4.5% | -5.4% | -1.5% | |
| Q3 2021 | -7.2% | -13.2% | -23.2% | |
| Q2 2021 | -4.9% | -10.3% | +6.5% | |
| Q1 2021 | -9.5% | -8.5% | +17.5% | |
| Q4 2020 | -9.9% | -6.9% | +2.3% | |
| Q3 2020 | -3.3% | -2.6% | +12.3% | |
| Q2 2020 | +0.1% | -1.1% | +19.8% | |
| Q1 2020 | +17.1% | +18.9% | +22.4% | |
| Q1 2019 | +17.1% | +18.9% | +22.4% | |
| Q1 2018 | -1.5% | -18.2% | -4.7% | |
| Q4 2019 | -1.5% | -18.2% | -4.7% | |
| Q3 2018 | +20.0% | -7.0% | -6.1% | |
| Q3 2019 | +18.2% | +30.3% | +32.9% | |
| Q2 2018 | -6.9% | -9.0% | -33.8% | |
| Q2 2019 | -6.9% | -9.0% | -33.8% | |
| Q4 2018 | -6.9% | -9.0% | -33.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro